Your browser doesn't support javascript.
loading
Intranasally Delivered Adenoviral Vector Protects Chickens against Newcastle Disease Virus: Vaccine Manufacturing and Stability Assessments for Liquid and Lyophilized Formulations.
Farnós, Omar; Martins Fernandes Paes, Barbara Cristina; Getachew, Belayneh; Rourou, Samia; Chaabene, Ameni; Gelaye, Esayas; Tefera, Takele A; Kamen, Amine A.
Afiliación
  • Farnós O; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada.
  • Martins Fernandes Paes BC; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada.
  • Getachew B; Research and Development Directorate, National Veterinary Institute, Bishoftu P.O. Box 19, Ethiopia.
  • Rourou S; Laboratory of Molecular Microbiology, Vaccinology and Biotechnology Development, Group of Biotechnology Development, Institut Pasteur de Tunis, Université Tunis El Manar, 13, Place Pasteur. BP.74., Tunis 1002, Tunisia.
  • Chaabene A; Laboratory of Molecular Microbiology, Vaccinology and Biotechnology Development, Group of Biotechnology Development, Institut Pasteur de Tunis, Université Tunis El Manar, 13, Place Pasteur. BP.74., Tunis 1002, Tunisia.
  • Gelaye E; Research and Development Directorate, National Veterinary Institute, Bishoftu P.O. Box 19, Ethiopia.
  • Tefera TA; Research and Development Directorate, National Veterinary Institute, Bishoftu P.O. Box 19, Ethiopia.
  • Kamen AA; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada.
Vaccines (Basel) ; 12(1)2023 Dec 29.
Article en En | MEDLINE | ID: mdl-38250854
ABSTRACT
Newcastle disease (ND) remains a critical disease affecting poultry in sub-Saharan Africa. In some countries, repeated outbreaks have a major impact on local economies and food security. Recently, we developed an adenovirus-vectored vaccine encoding the Fusion protein from an Ethiopian isolate of Newcastle disease virus (NDV). The adenoviral vector was designed, and a manufacturing process was developed in the context of the Livestock Vaccine Innovation Fund initiative funded by the International Development Research Centre (IDRC) of Canada. The industrially relevant recombinant vaccine technology platform is being transferred to the National Veterinary Institute (Ethiopia) for veterinary applications. Here, a manufacturing process using HEK293SF suspension cells cultured in stirred-tank bioreactors for the vaccine production is proposed. Taking into consideration supply chain limitations, options for serum-free media selection were evaluated. A streamlined downstream process including a filtration, an ultrafiltration, and a concentration step was developed. With high volumetric yields (infectious titers up to 5 × 109 TCID50/mL) in the culture supernatant, the final formulations were prepared at 1010 TCID50/mL, either in liquid or lyophilized forms. The liquid formulation was suitable and safe for mucosal vaccination and was stable for 1 week at 37 °C. Both the liquid and lyophilized formulations were stable after 6 months of storage at 4 °C. We demonstrate that the instillation of the adenoviral vector through the nasal cavity can confer protection to chickens against a lethal challenge with NDV. Overall, a manufacturing process for the adenovirus-vectored vaccine was developed, and protective doses were determined using a convenient route of delivery. Formulation and storage conditions were established, and quality control protocols were implemented.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Canadá